Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

laboratorios liconsa, s.a. - losartan - filmsko obložena tableta - losartan 91,52 mg / 1 tabletakalijev losartanat - losartan

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

laboratorios liconsa, s.a. - losartan - filmsko obložena tableta - losartan 45,76 mg / 1 tableta - losartan

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

laboratorios liconsa, s.a. - losartan - filmsko obložena tableta - losartan 45,76 mg / 1 tabletakalijev losartanat - losartan

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

ferring gmbh - mizoprostol - vaginalni dostavni sistem - mizoprostol 200 µg / 1 dostavni sistem - mizoprostol

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

laboratorios liconsa, s.a. - losartan - filmsko obložena tableta - losartan 11,44 mg / 1 tableta kalijev losartanat - losartan

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

laboratorios liconsa, s.a. - losartan - filmsko obložena tableta - losartan 91,52 mg / 1 tableta kalijev losartanat - losartan

Evropska unija - slovenščina - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor - cistična fibroza - drugi proizvodi dihal - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 in 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 in 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.

Evropska unija - slovenščina - EMA (European Medicines Agency)

advanz pharma limited - obeticholic kisline - ciroza jeter, biliary - terapija z jetri in jeter - ocaliva je indicirano za zdravljenje primarnim holangitisom žolčem (znan tudi kot primarna biliarna ciroza) v kombinaciji z ursodeoxycholic kisline (udca) pri odraslih s nezadosten odziv na udca ali kot monoterapijo pri odraslih ni mogoče prenašati udca.

Evropska unija - slovenščina - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - lumacaftor, ivacaftor - cistična fibroza - drugi proizvodi dihal - orkambi tablete so primerna za zdravljenje cistična fibroza (cf) pri bolnikih, starih 6 let in več, ki so homozygous za f508del mutacije v cftr gena. orkambi granules are indicated for the treatment of cystic fibrosis (cf) in children aged 1 year and older who are homozygous for the f508del mutation in the cftr gene.

Evropska unija - slovenščina - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - tezacaftor, ivacaftor - cistična fibroza - drugi proizvodi dihal - symkevi is indicated in a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (cf) aged 6 years and older who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t.